Harrow Inc Com – Filings and Transcripts

NASDAQ: HROW
Share price (11/6/26): $26.89
Market cap (11/6/26): $1.008 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 06/30/26 Q2

ended 03/31/26 Q1

ended 12/31/25 FY 2025

ended 09/30/25 Q3

ended 06/30/25 Q2

Prospectuses and Registrations Filter

Removal from listing

Removal from listing

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Ownership Filter

Opaleye Management Inc.

Opaleye Management Inc.

News Filter

Closes Acquisition of TYRVAYA® First and Only FDA-Approved Nasal Spray for Dry Eye Disease Adds a Differentiated, Drop-Free Treatment Option to Harrow’s Growing Ocular Surface Franchise

Change in Directors, Officers or Compensation, Financial Statements or Exhibits

Announces Second Quarter 2026 Financial Results

Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Shareholder Vote Results

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Definitive proxy

Additional info about upcoming vote

Other Filter

Statement of eligibility as a trustee

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC